Analyzing the classification of 767 GBA1 variants to guide GBA1 PD risk prediction
Objective: To assess the consistency of GBA1 variant classification across large Parkinson’s disease (PD) and Gaucher disease (GD) cohorts and determine how variant-specific biochemical data…AI-based Progression and Medication Response Prediction in Parkinson’s Disease: the AI-PMP Study Protocol
Objective: To evaluate proof-of-concept performance of two artificial intelligence (AI) multivariable models predicting (1) motor disease progression and (2) treatment-related side effects over 12 months…Clinical and Biomarker Trajectories in GBA1 Non-Manifesting Carriers With and Without α-Synuclein Seed Amplification Positivity
Objective: To characterize clinical and biomarker features of GBA1-NMC and evaluate whether CSF-αSynSAA status is associated with longitudinal clinical progression and phenoconversion. Background: Pathogenic variants…Retrospective Evaluation of microRNA-7-5p and Neuron-Derived α-Synuclein in Prodromal Parkinson’s Disease as Phenoconversion Biomarkers
Objective: To determine if combining microRNA-7-5p (miR-7-5p) and neuron-derived extracellular vesicle (NDEV) α-synuclein (α-syn) would enrich prodromal Parkinson's disease (PD) subjects for those more likely to phenoconvert. Background: Studies have found blood…Association of Neurofilament Light Chain with Substantia Nigra Degeneration in Parkinson’s Disease
Objective: This study aims to investigate the association between serum neurofilament light chain (NfL), microstructural changes in the substantia nigra, and clinical manifestations in Parkinson’s…Prodromal Parkinson’s Disease in Singapore: Motor and Non-Motor Symptom Patterns
Objective: To determine the differences in motor and non-motor symptoms between subjects categorized as Low, Intermediate, or High Risk for future Parkinson’s Disease (PD). Background:…Predicting Dementia in Parkinson’s Disease Using Blood-Based Proteomics
Objective: To identify a proteomic profile associated with the future development of dementia in recently diagnosed Parkinson’s disease (PD) patients. Background: Dementia is a common…DTI-ALPS Insights into Glymphatic Dynamics and Neurovascular Changes in Parkinson’s Disease
Objective: To investigate glymphatic activity, structural small vessel disease (SVD) markers, and white matter microstructure in Parkinson’s disease (PD) patients, and to explore their associations…NLRP3 Inhibition in Early-Stage Parkinson’s disease: Results of a Phase Ib Study
Objective: To evaluate the effect of selnoflast, an NLRP3 inhibitor, in persons with early-stage Parkinson’s disease (PD). Background: Damage-associated molecular patterns and pathological alpha-synuclein from damaged or…Risk Factors and Etiologies for Emergency Visit among Parkinson´s Disease Patients: a Narrative Review
Objective: The objective of this study is to understand various risk factors and etiologies of PD patients for admission at emergency department. Background: Parkinson´s Disease…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 553
- Next Page »